Back

Daprodustat in patients with heart failure and renal anemia: multicenter, open-label, randomized controlled study

17 May 2025 (12:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Tailored therapeutics advances in heart failure Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Yu Suresvar Singh

Juntendo University Graduate School of Medicine, Tokyo (Japan)

5 More presentations in this session

Presentation thumbnail
Telemonitored standardized titration for heart failure with reduced ejection fraction, an open clinical cohort study.
Associate Professor N. Bergh (Gothenburg, SE)
Abstract Slides Video
Presentation thumbnail
The in-hospital use of SGLT2i in heart failure with ischemic aetiology and recent acute coronary syndrome
Doctor A. D'Amato (Rome, IT)
Abstract Slides Video
Presentation thumbnail
Effect of angiotensin converting enzyme inhibitors versus angiotensin receptor blockers on all-cause mortality in heart failure patients receiving quadruple guideline directed medical therapy
Assistant Professor A. Sahin (Canakkale, TR)
Abstract Slides Video
Presentation thumbnail
Phenomapping-derived tool to individualize the effect of sacubitril/valsartan in heart failure with preserved ejection fraction
Associate Professor J. Park (Seongnam, KR)
Abstract Slides Video
Presentation thumbnail
Finerenone in patients with heart failure and deterioration in eGFR to <25ml/min/1.73m2 in the FINEARTS-HF Trial
Doctor S. Chatur (Boston, US)
Abstract Slides

Access the full session

Session thumbnail
Tailored therapeutics advances in heart failure

The Event

Event poster

Heart Failure 2025

17 May 2025 12:00 CET
You may be interested in
thumbnail
Congress Presentation
Uncoupling erythropoiesis from cardiorenal effects: SGLT2 inhibition in non-diabetic heart failure
thumbnail
Congress Presentation
Effects of SGLT-2 inhibitors on erythropoiesis and the associated cardio-renal benefits in patients with chronic heart failure
thumbnail
Congress Session
Late breaking clinical trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources